PCI-32765 Racemate (BioDeep_00000714589)
代谢物信息卡片
PCI-32765 (Racemate)
化学式: C25H24N6O2 (440.19606439999995)
中文名称: Ibrutinib Racemate
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
InChI: InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Zhiquan Xiang, Klaudia Kuranda, William Quinn, Areski Chekaoui, Robert Ambrose, Mohadeseh Hasanpourghai, Mikhail Novikov, Dakota Newman, Christina Cole, Xiangyang Zhou, Federico Mingozzi, Hildegund C J Ertl. The Effect of Rapamycin and Ibrutinib on Antibody Responses to Adeno-Associated Virus Vector-Mediated Gene Transfer.
Human gene therapy.
2022 06; 33(11-12):614-624. doi:
10.1089/hum.2021.258. [PMID: 35229644] - Bing Xu, Xiaozhe Liu, Shihao Gao. IL2-inducible T-cell kinase inhibitor ibrutinib reduces symptoms and Th2 differentiation in mouse allergic-rhinitis model.
Drug development research.
2022 04; 83(2):544-551. doi:
10.1002/ddr.21884. [PMID: 34609751] - Li Li, Zhujun Li, Conghua Lu, Jianghua Li, Kejun Zhang, Caiyu Lin, Xiaolin Tang, Zhulin Liu, Yimin Zhang, Rui Han, Yubo Wang, Mingxia Feng, Yuan Zhuang, Chen Hu, Yong He. Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling.
Communications biology.
2022 02; 5(1):155. doi:
10.1038/s42003-022-03111-7. [PMID: 35197546] - Giorgio Santoni, Consuelo Amantini, Federica Maggi, Oliviero Marinelli, Matteo Santoni, Maria Beatrice Morelli. The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment.
Biomolecules.
2022 01; 12(1):. doi:
10.3390/biom12010107. [PMID: 35053255] - Chen Guang Yu, Vimala Bondada, Hina Iqbal, Kate L Moore, John C Gensel, Subbarao Bondada, James W Geddes. Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and Promotes Recovery after Spinal Cord Injury.
International journal of molecular sciences.
2021 Dec; 23(1):. doi:
10.3390/ijms23010355. [PMID: 35008785] - Andreas J Steck. Anti-MAG neuropathy: From biology to clinical management.
Journal of neuroimmunology.
2021 12; 361(?):577725. doi:
10.1016/j.jneuroim.2021.577725. [PMID: 34610502] - Simantini Ghosh, Zaidan Mohammed, Itender Singh. Bruton's tyrosine kinase drives neuroinflammation and anxiogenic behavior in mouse models of stress.
Journal of neuroinflammation.
2021 Dec; 18(1):289. doi:
10.1186/s12974-021-02322-9. [PMID: 34895246] - David E Spaner, Yuxuan Luo, Guizhei Wang, Jennifer Gallagher, Hubert Tsui, Yonghong Shi. Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.
Cancer medicine.
2021 12; 10(24):8789-8798. doi:
10.1002/cam4.4378. [PMID: 34791813] - Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Puran Chen, Gunnar Söderdahl, Anders Österborg, C I Edvard Smith, David Wullimann, Jan Vesterbacka, Gustaf Lindgren, Lisa Blixt, Gustav Friman, Emilie Wahren-Borgström, Anna Nordlander, Angelica Cuapio Gomez, Mira Akber, Davide Valentini, Anna-Carin Norlin, Anders Thalme, Gordana Bogdanovic, Sandra Muschiol, Peter Nilsson, Sophia Hober, Karin Loré, Margaret Sällberg Chen, Marcus Buggert, Hans-Gustaf Ljunggren, Per Ljungman, Soo Aleman. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
EBioMedicine.
2021 Dec; 74(?):103705. doi:
10.1016/j.ebiom.2021.103705. [PMID: 34861491] - Csilla Markóth, Ibolya File, Róbert Szász, László Bidiga, József Balla, János Mátyus. Ibrutinib-induced acute kidney injury via interstitial nephritis.
Renal failure.
2021 Dec; 43(1):335-339. doi:
10.1080/0886022x.2021.1874985. [PMID: 33567947] - Alessio Bruscaggin, Lodovico Terzi di Bergamo, Valeria Spina, Brendan Hodkinson, Gabriela Forestieri, Ferdinando Bonfiglio, Adalgisa Condoluci, Wei Wu, Maria C Pirosa, Martin R Faderl, Ricardo Koch, Michael Schaffer, John D Alvarez, Nele Fourneau, Bernhard Gerber, Georg Stussi, Emanuele Zucca, Sriram Balasubramanian, Davide Rossi. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.
Blood advances.
2021 11; 5(22):4674-4685. doi:
10.1182/bloodadvances.2021004528. [PMID: 34500472] - Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey V Matous, David MacDonald, Constantine S Tam, Olivier Tournilhac, Shuo Ma, Steven P Treon, Albert Oriol, Jerry Ping, Eva M Briso, Israel Arango-Hisijara, Meletios A Dimopoulos. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021 11; 27(21):5793-5800. doi:
10.1158/1078-0432.ccr-21-1497. [PMID: 34380643] - Noriko Doki, Masako Toyosaki, Souichi Shiratori, Tomoo Osumi, Masaya Okada, Toshiro Kawakita, Masashi Sawa, Takayuki Ishikawa, Yasunori Ueda, Nozomi Yoshinari, Susumu Nakahara. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Transplantation and cellular therapy.
2021 10; 27(10):867.e1-867.e9. doi:
10.1016/j.jtct.2021.05.019. [PMID: 34102349] - G Ishdorj, Z Nugent, M Squires, S Kost, V Banerji, L Davidson, C S Katyal, A Marshall, S B Gibson, J B Johnston. Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.
Leukemia research.
2021 10; 109(?):106628. doi:
10.1016/j.leukres.2021.106628. [PMID: 34134067] - Riccardo Moia, Chiara Favini, Valentina Ferri, Gabriela Forestieri, Lodovico Terzi Di Bergamo, Mattia Schipani, Sruthi Sagiraju, Annalisa Andorno, Silvia Rasi, Ramesh Adhinaveni, Donatella Talotta, Wael Al Essa, Lorenzo De Paoli, Gloria Margiotta Casaluci, Andrea Patriarca, Renzo L Boldorini, Davide Rossi, Gianluca Gaidano. Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
British journal of haematology.
2021 10; 195(1):108-112. doi:
10.1111/bjh.17718. [PMID: 34291829] - Hee Jeong Cho, Dong Won Baek, Juhyung Kim, Jung Min Lee, Joon Ho Moon, Sang Kyun Sohn. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
Expert review of hematology.
2021 09; 14(9):819-830. doi:
10.1080/17474086.2021.1967139. [PMID: 34375536] - Tensei Hirasawa, Masafumi Kikuchi, Kensuke Shigeta, Shinya Takasaki, Yu Sato, Toshihiro Sato, Jiro Ogura, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Masamitsu Maekawa, Nariyasu Mano. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Biomedical chromatography : BMC.
2021 Aug; 35(8):e5124. doi:
10.1002/bmc.5124. [PMID: 33772839] - Stefania Fiorcari, Claudio Giacinto Atene, Rossana Maffei, Giulia Debbia, Leonardo Potenza, Mario Luppi, Roberto Marasca. Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection.
Haematologica.
2021 08; 106(8):2265-2268. doi:
10.3324/haematol.2020.277392. [PMID: 33691383] - Chiara Brullo, Carla Villa, Bruno Tasso, Eleonora Russo, Andrea Spallarossa. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
International journal of molecular sciences.
2021 Jul; 22(14):. doi:
10.3390/ijms22147641. [PMID: 34299259] - Satyavani Kaliamurthi, Gurudeeban Selvaraj, Chandrabose Selvaraj, Sanjeev Kumar Singh, Dong-Qing Wei, Gilles H Peslherbe. Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
International journal of molecular sciences.
2021 Jun; 22(13):. doi:
10.3390/ijms22137071. [PMID: 34209188] - Julie Belliere, Audrey Casemayou, Eloïse Colliou, Hélène El Hachem, Clément Kounde, Alexis Piedrafita, Guylène Feuillet, Joost P Schanstra, Stanislas Faguer. Ibrutinib does not prevent kidney fibrosis following acute and chronic injury.
Scientific reports.
2021 06; 11(1):11985. doi:
10.1038/s41598-021-91491-x. [PMID: 34099830] - Mariela Sivina, Lianchun Xiao, Ekaterina Kim, Alicia Vaca, Shih-Shih Chen, Michael J Keating, Alessandra Ferrajoli, Zeev Estrov, Nitin Jain, William G Wierda, Xuelin Huang, Nicholas Chiorazzi, Jan A Burger. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.
Leukemia.
2021 06; 35(6):1610-1620. doi:
10.1038/s41375-020-01063-7. [PMID: 33087831] - H Yesid Estupiñán, Qing Wang, Anna Berglöf, Gerard C P Schaafsma, Yuye Shi, Litao Zhou, Dara K Mohammad, Liang Yu, Mauno Vihinen, Rula Zain, C I Edvard Smith. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Leukemia.
2021 05; 35(5):1317-1329. doi:
10.1038/s41375-021-01123-6. [PMID: 33526860] - Mutasim Al-Ghazawi, Mohammad I Saleh, Omaima Najib, Isam Salem, Naji Najib. Population Pharmacokinetics of Ibrutinib in Healthy Adults.
European journal of drug metabolism and pharmacokinetics.
2021 May; 46(3):405-413. doi:
10.1007/s13318-021-00679-z. [PMID: 33740218] - Miran Rada, Zahraa Qusairy, Marta Massip-Salcedo, Salvador Macip. Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy.
Molecular cancer research : MCR.
2021 04; 19(4):549-554. doi:
10.1158/1541-7786.mcr-20-0814. [PMID: 33328281] - Suzanne Maynard, Jose Ros-Soto, Aris Chaidos, Andrew Innes, Krushika Paleja, Eitan Mirvis, Noora Buti, Harriet Sharp, Renuka Palanicawandar, Dragana Milojkovic. The role of ibrutinib in COVID-19 hyperinflammation: A case report.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2021 Apr; 105(?):274-276. doi:
10.1016/j.ijid.2021.02.056. [PMID: 33607304] - Illias Tazi. [Antineoplasic drug repurposing in hematology for COVID-19 treatment].
Bulletin du cancer.
2021 Apr; 108(4):435-437. doi:
10.1016/j.bulcan.2020.12.009. [PMID: 33663776] - Lucía Quintana-Castanedo, Ander Mayor-Ibarguren, Eloy Tarín-Vicente, Pedro Herranz-Pinto. Ibrutinib-induced leg ulcer successfully treated with platelet-rich plasma.
Dermatologic therapy.
2021 03; 34(2):e14874. doi:
10.1111/dth.14874. [PMID: 33580976] - Fehmi Hindilerden, İpek Yönal Hindilerden, Reyhan Diz Küçükkaya. Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection.
Balkan medical journal.
2021 03; 38(2):141-142. doi:
10.4274/balkanmedj.galenos.2020.2020.9.106. [PMID: 33045824] - Johannes J M Rood, Amer Jamalpoor, Stephanie van Hoppe, Matthijs J van Haren, Roeland E Wasmann, Manoe J Janssen, Alfred H Schinkel, Rosalinde Masereeuw, Jos H Beijnen, Rolf W Sparidans. Extrahepatic metabolism of ibrutinib.
Investigational new drugs.
2021 02; 39(1):1-14. doi:
10.1007/s10637-020-00970-x. [PMID: 32623551] - Brooke Benner, William E Carson. Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
Journal of hematology & oncology.
2021 01; 14(1):15. doi:
10.1186/s13045-020-00999-8. [PMID: 33441177] - Ahmed Nadeem, Sheikh F Ahmad, Naif O Al-Harbi, Khalid E Ibrahim, Faleh Alqahtani, Wael A Alanazi, Hafiz M Mahmood, Sary Alsanea, Sabry M Attia. Bruton's tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice.
International immunopharmacology.
2021 Jan; 90(?):107123. doi:
10.1016/j.intimp.2020.107123. [PMID: 33168411] - K Baďurová, J Gregorová, M Vlachová, M Krejčí, S Ševčíková. Waldenström macroglobulinemia.
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.
2021; 34(6):428-433. doi:
10.48095/ccko2021428. [PMID: 34911327] - Tamim Alsuliman, Sylvia Faict, Florent Malard, Alexis Genthon, Eolia Brissot, Zoé Van de Wyngaert, Souhila Ikhlef, Anne Banet, Simona Lapusan, Simona Sestili, Elise Corre, Fella M'hammedi-Bouzina, Louis Schaeffer, Ollivier Legrand, Rémy Dulery, Mohamad Mohty, Zora Marjanovic. Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?.
Current research in translational medicine.
2021 01; 69(1):103273. doi:
10.1016/j.retram.2020.103273. [PMID: 33460953] - Hassaan Jafri, Isna Khan, Adarsh Sidda, Noman Ahmed Jang Khan, Murad Kheetan, Doreen Griswold, Toni Pacioles. Waldenstrom Macroglobulinemia Manifesting as Acute Kidney Injury and Bing-Neel Syndrome With Excellent Response to Ibrutinib.
Journal of investigative medicine high impact case reports.
2021 Jan; 9(?):23247096211021228. doi:
10.1177/23247096211021228. [PMID: 34078157] - Joi Ninomoto, Ahmad Mokatrin, Taisei Kinoshita, Carol Marimpietri, Terrance D Barrett, Betty Y Chang, Juthamas Sukbuntherng, Danelle F James, Mark Crowther. Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
Hematology (Amsterdam, Netherlands).
2020 Dec; 25(1):112-117. doi:
10.1080/16078454.2020.1730080. [PMID: 32131714] - Fotiou Despina, Dimopoulos Meletios Athanasios, Kastritis Efstathios. Emerging drugs for the treatment of Waldenström macroglobulinemia.
Expert opinion on emerging drugs.
2020 12; 25(4):433-444. doi:
10.1080/14728214.2020.1822816. [PMID: 32955949] - Zheli Jiang, Lu Shi, Yu Zhang, Guanyang Lin, Yingying Wang. Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2020 Nov; 191(?):113613. doi:
10.1016/j.jpba.2020.113613. [PMID: 32971496] - Raji E Joseph, Neha Amatya, D Bruce Fulton, John R Engen, Thomas E Wales, Amy Andreotti. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
eLife.
2020 11; 9(?):. doi:
10.7554/elife.60470. [PMID: 33226337] - Jan de Jong, Anna Mitselos, Wojciech Jurczak, Raul Cordoba, Carlos Panizo, Tomasz Wrobel, Monika Dlugosz-Danecka, James Jiao, Juthamas Sukbuntherng, Daniele Ouellet, Peter Hellemans. Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
Pharmacology research & perspectives.
2020 10; 8(5):e00649. doi:
10.1002/prp2.649. [PMID: 32945596] - Xiaoyun Liu, Dan Feng, Mingyue Zheng, Yongmei Cui, Dafang Zhong. Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins.
Drug metabolism and pharmacokinetics.
2020 Oct; 35(5):456-465. doi:
10.1016/j.dmpk.2020.07.002. [PMID: 32847720] - Zachary Z Brener, Heather Brener, Alexander Losev. Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2020 Oct; 26(7):1735-1737. doi:
10.1177/1078155220904406. [PMID: 32054411] - Fanny Gallais, Loïc Ysebaert, Fabien Despas, Sandra De Barros, Loïc Dupré, Anne Quillet-Mary, Caroline Protin, Fabienne Thomas, Lucie Obéric, Ben Allal, Etienne Chatelut, Mélanie White-Koning. Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
Clinical pharmacokinetics.
2020 09; 59(9):1171-1183. doi:
10.1007/s40262-020-00884-0. [PMID: 32328976] - Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, Giulia Quaresmini, Marina Motta, Candida Vitale, Jose Antonio Garcia-Marco, José Ángel Hernández-Rivas, Fatima Mirás, Mónica Baile, Juan Marquet, Carsten U Niemann, Gianluigi Reda, Talha Munir, Eva Gimeno, Monia Marchetti, Francesca Maria Quaglia, Marzia Varettoni, Julio Delgado, Sunil Iyengar, Ann Janssens, Roberto Marasca, Angela Ferrari, Carolina Cuéllar-García, Gilad Itchaki, Martin Špaček, Lorenzo De Paoli, Luca Laurenti, Mark-David Levin, Enrico Lista, Francesca R Mauro, Martin Šimkovič, Ellen Van Der Spek, Elisabeth Vandenberghe, Livio Trentin, Ewa Wasik-Szczepanek, Rosa Ruchlemer, Dominique Bron, Maria Rosaria De Paolis, Giovanni Del Poeta, Lucia Farina, Myriam Foglietta, Massimo Gentile, Yair Herishanu, Tobias Herold, Ozren Jaksic, Arnon P Kater, Sabina Kersting, Lara Malerba, Lorella Orsucci, Viola Maria Popov, Paolo Sportoletti, Mohamed Yassin, Barbara Pocali, Gabor Barna, Annalisa Chiarenza, Gimena Dos Santos, Eugene Nikitin, Martin Andres, Maria Dimou, Michael Doubek, Alicia Enrico, Yervand Hakobyan, Olga Kalashnikova, Macarena Ortiz Pareja, Maria Papaioannou, Davide Rossi, Nimish Shah, Amit Shrestha, Oana Stanca, Niki Stavroyianni, Vladimir Strugov, Constantine Tam, Mihnea Zdrenghea, Marta Coscia, Kostas Stamatopoulos, Giuseppe Rossi, Alessandro Rambaldi, Emili' Montserrat, Robin Foà, Antonio Cuneo, Paolo Ghia. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Leukemia.
2020 09; 34(9):2354-2363. doi:
10.1038/s41375-020-0959-x. [PMID: 32647324] - Raul Cordoba. Bringing hospital care closer to patients amidst COVID-19.
The Lancet. Haematology.
2020 09; 7(9):e637. doi:
10.1016/s2352-3026(20)30259-3. [PMID: 32853582] - Maria Gavriatopoulou, Despina Fotiou, Ioannis Ntanasis-Stathopoulos, Meletios Athanasios Dimopoulos. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
Expert review of anticancer therapy.
2020 08; 20(8):663-674. doi:
10.1080/14737140.2020.1791705. [PMID: 32631091] - Moritz Fürstenau, Petra Langerbeins, Nisha De Silva, Anna Maria Fink, Sandra Robrecht, Julia von Tresckow, Florian Simon, Karin Hohloch, Jolanda Droogendijk, Marjolein van der Klift, Ellen van der Spek, Thomas Illmer, Björn Schöttker, Kirsten Fischer, Clemens M Wendtner, Eugen Tausch, Stephan Stilgenbauer, Carsten U Niemann, Michael Gregor, Arnon P Kater, Michael Hallek, Barbara Eichhorst. COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
Leukemia.
2020 08; 34(8):2225-2229. doi:
10.1038/s41375-020-0941-7. [PMID: 32601378] - Elise A Chong, Lindsey E Roeker, Mazyar Shadman, Matthew S Davids, Stephen J Schuster, Anthony R Mato. BTK Inhibitors in Cancer Patients with COVID-19: 'The Winner Will be the One Who Controls That Chaos' (Napoleon Bonaparte).
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 07; 26(14):3514-3516. doi:
10.1158/1078-0432.ccr-20-1427. [PMID: 32345646] - Eric P Allain, Michèle Rouleau, Katrina Vanura, Sophie Tremblay, Joanie Vaillancourt, Vincent Bat, Patrick Caron, Lyne Villeneuve, Adrien Labriet, Véronique Turcotte, Trang Le, Medhat Shehata, Susanne Schnabl, Dita Demirtas, Rainer Hubmann, Charles Joly-Beauparlant, Arnaud Droit, Ulrich Jäger, Philipp B Staber, Eric Lévesque, Chantal Guillemette. UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
British journal of cancer.
2020 07; 123(2):240-251. doi:
10.1038/s41416-020-0887-6. [PMID: 32418995] - Tycho Baumann, Julio Delgado, Emili Montserrat. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
Leukemia.
2020 07; 34(7):1954-1956. doi:
10.1038/s41375-020-0870-5. [PMID: 32433507] - Santiago Thibaud, Douglas Tremblay, Sheena Bhalla, Brittney Zimmerman, Keith Sigel, Janice Gabrilove. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
British journal of haematology.
2020 07; 190(2):e73-e76. doi:
10.1111/bjh.16863. [PMID: 32433778] - L H Sehn, P Kuruvilla, A Christofides, J Stakiw. Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic.
Current oncology (Toronto, Ont.).
2020 06; 27(3):e332-e335. doi:
10.3747/co.27.6769. [PMID: 32669941] - Ewa Lewicka, Paulina Daniluk, Zofia Lasocka, Ewa Zarzycka, Alicja Dąbrowska-Kugacka, Izabela Nabiałek-Trojanowska, Jan M Zaucha. Assessment of dabigatran plasma concentration may improve the safety of anticoagulation in patients treated with ibrutinib with concomitant atrial fibrillation.
Kardiologia polska.
2020 05; 78(5):454-457. doi:
10.33963/kp.15255. [PMID: 32210217] - Steven P Treon, Jorge J Castillo, Alan P Skarbnik, Jacob D Soumerai, Irene M Ghobrial, Maria Luisa Guerrera, Kirsten Meid, Guang Yang. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
Blood.
2020 05; 135(21):1912-1915. doi:
10.1182/blood.2020006288. [PMID: 32302379] - Stephanie Jordaens, Leah Cooksey, Stephanie Bonney, Laurence Orchard, Matthew Coutinho, Viggo Van Tendeloo, Ken I Mills, Kim Orchard, Barbara-Ann Guinn. Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.
British journal of haematology.
2020 05; 189(3):500-512. doi:
10.1111/bjh.16407. [PMID: 32064588] - Tuija Tapaninen, Aleksi M Olkkola, Aleksi Tornio, Mikko Neuvonen, Erkki Elonen, Pertti J Neuvonen, Mikko Niemi, Janne T Backman. Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction.
Clinical and translational science.
2020 03; 13(2):345-351. doi:
10.1111/cts.12716. [PMID: 31664782] - Shuangshuang Sun, Dongfang Cheng, Shumeng Kong, Xiangping Li, Tongfang Li, Qinglong Yu, Lin Wang. A rapid and sensitive method for quantification of ibrutinib in rat plasma by UPLC-ESI-MS/MS: validation and application to pharmacokinetic studies of a novel ibrutinib nanocrystalline.
Biomedical chromatography : BMC.
2020 Jan; 34(1):e4703. doi:
10.1002/bmc.4703. [PMID: 31629393] - Juliana Velez Lujan, Paula A Lengerke-Diaz, Chaja Jacobs, Eider F Moreno-Cortes, Cesar A Ramirez-Segura, Michael Y Choi, Colin McCarthy, Alaina Heinen, Thomas J Kipps, Januario E Castro. Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.
Haematologica.
2020 01; 105(1):e22-e25. doi:
10.3324/haematol.2018.212597. [PMID: 31048356] - Caroline E O'Riordan, Gareth S D Purvis, Debora Collotta, Nadine Krieg, Bianka Wissuwa, Madeeha H Sheikh, Gustavo Ferreira Alves, Shireen Mohammad, Lauren A Callender, Sina M Coldewey, Massimo Collino, David R Greaves, Christoph Thiemermann. X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure.
Frontiers in immunology.
2020; 11(?):581758. doi:
10.3389/fimmu.2020.581758. [PMID: 33162995] - Gasim Dobie, Fahd A Kuriri, Musab M A Omar, Fehaid Alanazi, Ali M Gazwani, Chloe P S Tang, Daniel Man-Yuen Sze, Sasanka M Handunnetti, Constantine Tam, Denise E Jackson. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.
Blood advances.
2019 12; 3(24):4298-4311. doi:
10.1182/bloodadvances.2019000640. [PMID: 31869418] - Alessandro Prezzo, Filomena Monica Cavaliere, Caterina Bilotta, Tancredi Massimo Pentimalli, Metello Iacobini, Laura Cesini, Robin Foà, Francesca Romana Mauro, Isabella Quinti. Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
Leukemia research.
2019 12; 87(?):106233. doi:
10.1016/j.leukres.2019.106233. [PMID: 31639635] - Shimoli V Barot, Sarah S Lee, Bhumika J Patel, Jason N Valent. Ibrutinib is Effective in Refractory Type II Cryoglobulinemia.
Clinical lymphoma, myeloma & leukemia.
2019 12; 19(12):e629-e632. doi:
10.1016/j.clml.2019.07.442. [PMID: 31585822] - Apabrita Ayan Das, Devasmita Chakravarty, Debmalya Bhunia, Surajit Ghosh, Prakash C Mandal, Khawer N Siddiqui, Arun Bandyopadhyay. Elevated level of circulatory sTLT1 induces inflammation through SYK/MEK/ERK signalling in coronary artery disease.
Clinical science (London, England : 1979).
2019 11; 133(22):2283-2299. doi:
10.1042/cs20190999. [PMID: 31713591] - Sunita Keshari, Apriska Dewi Sipayung, Ching-Chuan Hsieh, Li-Jen Su, Yun-Ru Chiang, Huan-Cheng Chang, Wu-Chang Yang, Tsung-Hsien Chuang, Chien-Lung Chen, Chun-Ming Huang. IL-6/p-BTK/p-ERK signaling mediates calcium phosphate-induced pruritus.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
2019 11; 33(11):12036-12046. doi:
10.1096/fj.201900016rr. [PMID: 31365830] - Jennifer Series, Cédric Garcia, Marie Levade, Julien Viaud, Pierre Sié, Loïc Ysebaert, Bernard Payrastre. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
Haematologica.
2019 11; 104(11):2292-2299. doi:
10.3324/haematol.2018.207183. [PMID: 30819914] - Porntipa Korprasertthaworn, Nuy Chau, Pramod C Nair, Andrew Rowland, John O Miners. Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202.
Biochemical pharmacology.
2019 11; 169(?):113616. doi:
10.1016/j.bcp.2019.08.018. [PMID: 31445021] - Xuedong Yang, Zhenhao Cao, Peigang Wu, Zhong Li. Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers.
Medical science monitor : international medical journal of experimental and clinical research.
2019 Oct; 25(?):7951-7957. doi:
10.12659/msm.916950. [PMID: 31644524] - Antonin Papin, Benoit Tessoulin, Céline Bellanger, Anne Moreau, Yannick Le Bris, Hervé Maisonneuve, Philippe Moreau, Cyrille Touzeau, Martine Amiot, Catherine Pellat-Deceunynck, Steven Le Gouill, David Chiron. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
Leukemia.
2019 10; 33(10):2442-2453. doi:
10.1038/s41375-019-0463-3. [PMID: 30940906] - Ping Du, Yin Guan, Zhuoling An, Pengfei Li, Lihong Liu. A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study.
The Analyst.
2019 Sep; 144(18):5462-5471. doi:
10.1039/c9an00861f. [PMID: 31380858] - Sandhya Manohar, Anip Bansal, Rimda Wanchoo, Vipulbhai Sakhiya, Scott Lucia, Kenar D Jhaveri. Ibrutinib induced acute tubular injury: A case series and review of the literature.
American journal of hematology.
2019 09; 94(9):E223-E225. doi:
10.1002/ajh.25546. [PMID: 31148235] - Jacob D Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing, Yong Mun, Neil E Kay, Tait D Shanafelt, Kari G Rabe, John C Byrd, Asher A Chanan-Khan, Richard R Furman, Peter Hillmen, Jeffrey Jones, John F Seymour, Jeffrey P Sharman, Lucille Ferrante, Mehrdad Mobasher, Thomas Stark, Vijay Reddy, Lyndah K Dreiling, Pankaj Bhargava, Angela Howes, Danelle F James, Andrew D Zelenetz. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
The Lancet. Haematology.
2019 Jul; 6(7):e366-e374. doi:
10.1016/s2352-3026(19)30085-7. [PMID: 31109827] - Silvia Maria Lavezzi, Jan de Jong, Martine Neyens, Paula Cramer, Fatih Demirkan, Graeme Fraser, Nancy Bartlett, Marie-Sarah Dilhuydy, Javier Loscertales, Abraham Avigdor, Simon Rule, Olga Samoilova, Andre Goy, Siddhartha Ganguly, Mariya Salman, Angela Howes, Michelle Mahler, Giuseppe De Nicolao, Italo Poggesi. Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Pharmaceutical research.
2019 May; 36(7):93. doi:
10.1007/s11095-019-2605-8. [PMID: 31044267] - Jia Liu, Hanqing Liu, Qingqi Zeng. The effect of naringenin on the pharmacokinetics of ibrutinib in rat: A drug-drug interaction study.
Biomedical chromatography : BMC.
2019 May; 33(5):e4507. doi:
10.1002/bmc.4507. [PMID: 30754071] - Xiangjun Qiu, Qianmeng Lin, Zongdi Ning, Xin Qian, Pengbo Li, Lei Ye, Saili Xie. Quantitative bioanalytical assay for the human epidermal growth factor receptor (HER) inhibitor dacomitinib in rat plasma by UPLC-MS/MS.
Journal of pharmaceutical and biomedical analysis.
2019 Mar; 166(?):66-70. doi:
10.1016/j.jpba.2018.12.041. [PMID: 30612075] - Viola Denzinger, Kristina Busygina, Janina Jamasbi, Isabell Pekrul, Michael Spannagl, Christian Weber, Reinhard Lorenz, Wolfgang Siess. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Thrombosis and haemostasis.
2019 Mar; 119(3):397-406. doi:
10.1055/s-0039-1677744. [PMID: 30685871] - Takeo Yasu, Kenji Momo, Hiroshi Yasui, Seiichirou Kuroda. Simple determination of plasma ibrutinib concentration using high-performance liquid chromatography.
Biomedical chromatography : BMC.
2019 Mar; 33(3):e4435. doi:
10.1002/bmc.4435. [PMID: 30421802] - Amir Yosef, Emily Z Touloukian, Vinod E Nambudiri. Ibrutinib in the management of Waldenstrom macroglobulinemia.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2019 Mar; 25(2):434-441. doi:
10.1177/1078155218786037. [PMID: 29996737] - Frédéric Pouzoulet, Agusti Alentorn, Louis Royer-Perron, Franck Assayag, Karima Mokhtari, Dalila Labiod, Magali Le Garff-Tavernier, Mailys Daniau, Emmanuelle Menet, Matthieu Peyre, Anne Schnitzler, Justine Guegan, Frédéric Davi, Khê Hoang-Xuan, Carole Soussain. Primary CNS lymphoma patient-derived orthotopic xenograft model capture the biological and molecular characteristics of the disease.
Blood cells, molecules & diseases.
2019 03; 75(?):1-10. doi:
10.1016/j.bcmd.2018.11.005. [PMID: 30502564] - David Paul, Patheparapu Chandrakala, Shruti Surendran, Prasanth Bitla, Nanjappan Satheeshkumar. Pharmacokinetic interaction study of novel combination of palbociclib and sorafenib for hepatocellular carcinoma in SD rats.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Feb; 1108(?):25-31. doi:
10.1016/j.jchromb.2019.01.003. [PMID: 30660839] - Alexander P de Porto, Zhe Liu, Regina de Beer, Sandrine Florquin, Onno J de Boer, Rudi W Hendriks, Tom van der Poll, Alex F de Vos. Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia.
Molecular medicine (Cambridge, Mass.).
2019 01; 25(1):3. doi:
10.1186/s10020-018-0069-7. [PMID: 30646846] - Caroline E O'Riordan, Gareth S D Purvis, Debora Collotta, Fausto Chiazza, Bianka Wissuwa, Sura Al Zoubi, Lara Stiehler, Lukas Martin, Sina M Coldewey, Massimo Collino, Christoph Thiemermann. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
Frontiers in immunology.
2019; 10(?):2129. doi:
10.3389/fimmu.2019.02129. [PMID: 31552054] - Lisa S Chen, Prithviraj Bose, Nichole D Cruz, Yongying Jiang, Qi Wu, Philip A Thompson, Shuju Feng, Michael H Kroll, Wei Qiao, Xuelin Huang, Nitin Jain, William G Wierda, Michael J Keating, Varsha Gandhi. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
Blood.
2018 11; 132(21):2249-2259. doi:
10.1182/blood-2018-06-860593. [PMID: 30254130] - Stéphanie van Hoppe, Johannes J M Rood, Levi Buil, Els Wagenaar, Rolf W Sparidans, Jos H Beijnen, Alfred H Schinkel. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
Molecular pharmaceutics.
2018 11; 15(11):5124-5134. doi:
10.1021/acs.molpharmaceut.8b00702. [PMID: 30247919] - Marzia Palma, Aleksandra Krstic, Lucia Peña Perez, Anna Berglöf, Stephan Meinke, Qing Wang, K Emelie M Blomberg, Masood Kamali-Moghaddam, Qiujin Shen, Georg Jaremko, Jeanette Lundin, Ayla De Paepe, Petter Höglund, Eva Kimby, Anders Österborg, Robert Månsson, C I Edvard Smith. Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
British journal of haematology.
2018 10; 183(2):212-224. doi:
10.1111/bjh.15516. [PMID: 30125946] - Steven P Treon, Joshua Gustine, Kirsten Meid, Guang Yang, Lian Xu, Xia Liu, Maria Demos, Amanda Kofides, Nicholas Tsakmaklis, Jiaji G Chen, Manit Munshi, Gloria Chan, Toni Dubeau, Noopur Raje, Andrew Yee, Elizabeth O'Donnell, Zachary R Hunter, Jorge J Castillo. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018 09; 36(27):2755-2761. doi:
10.1200/jco.2018.78.6426. [PMID: 30044692] - D Beauvais, J-F Goossens, E Boyle, B Allal, T Lafont, E Chatelut, C Herbaux, F Morschhauser, S Genay, P Odou, C Danel. Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2018 Sep; 1093-1094(?):158-166. doi:
10.1016/j.jchromb.2018.06.026. [PMID: 30029202] - Imogen Moran, Akira Nguyen, Weng Hua Khoo, Danyal Butt, Katherine Bourne, Clara Young, Jana R Hermes, Maté Biro, Gary Gracie, Cindy S Ma, C Mee Ling Munier, Fabio Luciani, John Zaunders, Andrew Parker, Anthony D Kelleher, Stuart G Tangye, Peter I Croucher, Robert Brink, Mark N Read, Tri Giang Phan. Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes.
Nature communications.
2018 08; 9(1):3372. doi:
10.1038/s41467-018-05772-7. [PMID: 30135429] - Samantha M Jaglowski, Bruce R Blazar. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
Blood advances.
2018 08; 2(15):2012-2019. doi:
10.1182/bloodadvances.2018013060. [PMID: 30108109] - Christopher David Swan, Thomas Gottlieb. Cryptococcus neoformans empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature.
BMJ case reports.
2018 Jul; 2018(?):. doi:
10.1136/bcr-2018-224786. [PMID: 30021735] - J J M Rood, P J A Dormans, M J van Haren, J H M Schellens, J H Beijnen, R W Sparidans. Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2018 Jul; 1090(?):14-21. doi:
10.1016/j.jchromb.2018.05.011. [PMID: 29778873] - Bin Tang, Peixiao Tang, Jiawei He, Hongqin Yang, Hui Li. Characterization of the binding of a novel antitumor drug ibrutinib with human serum albumin: Insights from spectroscopic, calorimetric and docking studies.
Journal of photochemistry and photobiology. B, Biology.
2018 Jul; 184(?):18-26. doi:
10.1016/j.jphotobiol.2018.05.008. [PMID: 29777941] - Jiaji G Chen, Xia Liu, Manit Munshi, Lian Xu, Nicholas Tsakmaklis, Maria G Demos, Amanda Kofides, Maria Luisa Guerrera, Gloria G Chan, Christopher J Patterson, Kirsten Meid, Joshua Gustine, Toni Dubeau, Patricia Severns, Jorge J Castillo, Zachary R Hunter, Jinhua Wang, Sara J Buhrlage, Nathanael S Gray, Steven P Treon, Guang Yang. BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.
Blood.
2018 05; 131(18):2047-2059. doi:
10.1182/blood-2017-10-811752. [PMID: 29496671] - Lauriane Goldwirt, Kevin Beccaria, Alain Ple, Hélène Sauvageon, Samia Mourah. Ibrutinib brain distribution: a preclinical study.
Cancer chemotherapy and pharmacology.
2018 04; 81(4):783-789. doi:
10.1007/s00280-018-3546-3. [PMID: 29476222] - V K Patel, B Lamothe, M L Ayres, J Gay, J P Cheung, K Balakrishnan, C Ivan, J Morse, M Nelson, M J Keating, W G Wierda, J R Marszalek, V Gandhi. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Leukemia.
2018 04; 32(4):920-930. doi:
10.1038/leu.2017.321. [PMID: 29099493] - Sara Roman-Garcia, Sara V Merino-Cortes, Sofia R Gardeta, Marjolein J W de Bruijn, Rudi W Hendriks, Yolanda R Carrasco. Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
Frontiers in immunology.
2018; 9(?):2027. doi:
10.3389/fimmu.2018.02027. [PMID: 30237801] - Yu Xi Terence Law, Lui Shiong Lee. Sudden Flank Pain in a Patient Receiving Ibrutinib for Mantle Cell Lymphoma.
JAMA oncology.
2018 Jan; 4(1):118-119. doi:
10.1001/jamaoncol.2017.2720. [PMID: 28910460] - Irene Kim, Gordon Wu, Ning-Ning Chai, Andrew S Klein, Stanley Jordan. Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization.
Transplant immunology.
2017 12; 45(?):59-64. doi:
10.1016/j.trim.2017.09.003. [PMID: 28951258] - David Miklos, Corey S Cutler, Mukta Arora, Edmund K Waller, Madan Jagasia, Iskra Pusic, Mary E Flowers, Aaron C Logan, Ryotaro Nakamura, Bruce R Blazar, Yunfeng Li, Stephen Chang, Indu Lal, Jason Dubovsky, Danelle F James, Lori Styles, Samantha Jaglowski. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Blood.
2017 11; 130(21):2243-2250. doi:
10.1182/blood-2017-07-793786. [PMID: 28924018] - Kangwei Wang, Xin Nie, Zhuona Rong, Tingting Fan, Juan Li, Xinxin Wang, Huiling Li, Jianyi Dong, Jun Chen, Fujin Wang, Jingyu Wang, Aiguo Wang. B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice.
International journal of cancer.
2017 09; 141(6):1201-1214. doi:
10.1002/ijc.30823. [PMID: 28580661]